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ABSTRACT 
EVALUATING THE CLINICAL IMPACT OF PROVIDING 
HOME BLOOD PRESSURE MONITORS TO PATIENTS WITH 
ELEVATED OR HIGH BLOOD PRESSURE 
Many clinicians continue to diagnose hypertension based on office-based 
readings, despite the 2015 United States Preventive Services Task Force 
recommendation for the use of home or ambulatory blood pressure monitoring to 
confirm the diagnosis of hypertension prior to initiating treatment. Without 
obtaining blood pressure readings outside of the clinic environment, it is 
impossible to correctly diagnose hypertension, particularly regarding masked 
hypertension and white coat hypertension. 
Stanford Health Care implemented a quality improvement project that 
provided patients with a home blood pressure device to monitor out of clinic blood 
pressure readings. The purpose of the project was to improve clinical care at 
Stanford Health Care, to assess for treatment control in patients already diagnosed 
with hypertension, and to verify the diagnosis of hypertension in patients 
undiagnosed. There were 98 subjects who had elevated or high blood pressure 
readings in the clinic who agreed to participate in the project. Findings showed 
that home blood pressure monitoring was effective in assessing for hypertension 
treatment control and verifying hypertensive phenotype in previously undiagnosed 
patients. Home blood pressure monitoring also allowed for timely diagnosis and 
treatment of hypertension. Providing home blood pressure devices to patients has 
the potential to reduce morbidity and mortality related to hypertension, reduce 
economic burden, and contribute to national quality initiatives that contribute to 
the overall health of the nation. 
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 CHAPTER 1: INTRODUCTION 
Management of hypertension is a public health challenge. Approximately 1 
in 3 United States adults has hypertension (Centers for Disease Control (CDC), 
2016). New hypertension screening guidelines published in 2017 by the American 
Heart Association (AHA) and the American College of Cardiology (ACC) 
aggressively defines hypertension as having a systolic blood pressure (SBP) 
greater than 130 mmHg or a diastolic blood pressure (DBP) greater than 80 
mmHg. The stricter definition of hypertension resulted in a substantial increase in 
prevalence of United States adults with hypertension, which increased from 31.1% 
to 45.6% based on data from the 2011 to 2014 National Health and Nutrition 
Examination Survey (NHANES) (Muntner et al., 2018). Currently, of the United 
States adults with the diagnosis of hypertension, 47.8% have blood pressure 
control, which is far below the target of Healthy People 2020’s Leading Health 
Indicator initiative of having achieved 61.2% blood of pressure control (Office of 
Disease Prevention and Health Promotion (ODPHP), 2019).  
Many clinicians continue to diagnose hypertension based on clinic readings 
despite the 2015 United States Preventive Services Task Force (USPSTF) 
recommendation that out of clinic blood pressure measurements should be 
obtained in order to confirm the diagnosis of hypertension before starting 
pharmacologic treatment, unless contraindicated (Siu, 2015). The 2017 AHA and 
ACC guideline also recommends utilization of home or ambulatory blood pressure 
monitoring to confirm the diagnosis of hypertension (Whelton et al, 2018). These 
changes were implemented to take into account the limitations to blood pressure 
measurement in the clinic setting, including incorrect blood pressure measuring 
techniques, improper training of medical staff, limited number of clinic readings 
2 
available to make a definitive diagnosis, and the inability to monitor the natural 
changes in blood pressure over a 24-hour period (White & Gulati, 2015). 
Furthermore, by relying on clinic blood pressure measurements, it is impossible to 
correctly diagnose hypertension, particularly in regard to white coat hypertension 
and masked hypertension (Whelton et al., 2018). White coat hypertension refers to 
patients having high blood pressure in the clinic, but normal measurements in their 
natural environment (Siu, 2015). Masked hypertension is when a patient has 
normal blood pressure readings in the clinic, but high measurements in the 
ambulatory setting (Siu, 2015). Without home blood pressure monitoring, there is 
no way to identify patients with white coat hypertension or masked hypertension, 
resulting in misdiagnosis of hypertension.  
Stanford Health Care implemented a quality improvement project to 
improve clinical care and address the problem of misdiagnosis of hypertension due 
to lack of home blood pressure monitoring. Staff created a patient-centered, 
standardized blood pressure screening workflow using the health belief model as a 
theoretical framework to inform the workflow design. Patients who presented to 
the clinic with elevated or high blood pressure readings were provided a home 
blood pressure monitor, detailed information about high blood pressure and the 
consequences of untreated hypertension, and instruction on how to use the monitor 
at home. For patients already diagnosed with hypertension on anti-hypertensive 
medication, the home blood pressure monitor was provided to assess for treatment 
control. For patients undiagnosed with hypertension, the home blood pressure 
monitor was provided to confirm if the patient had normotension, sustained 
hypertension, white coat hypertension, or masked hypertension. A retrospective 
chart review was performed to evaluate the clinical impact of providing home 
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blood pressure monitors to patients with elevated or high blood blood pressure 
readings in the clinic setting.  
Background and Significance 
High blood pressure, or hypertension, is the most common chronic 
condition seen in an ambulatory setting in the United States (National Center for 
Health Statistics, 2015). Often called the silent killer because there are often no 
physical symptoms associated with high blood pressure, the consequence of 
untreated hypertension is target organ damage, which includes stroke, vision loss, 
heart attack, heart failure, kidney disease, sexual dysfunction, and peripheral 
arterial disease (AHA, 2016). In 2014, high blood pressure was a primary or 
contributing cause of death in the United States resulting in 1,100 deaths each day 
(CDC, 2016). Worldwide, it is estimated that 7.5 million deaths are the result of 
hypertension; this represents about 12.8% of all total deaths (World Health 
Organization, 2019).  
Hypertension is a major modifiable risk factor for cardiovascular disease 
and all-cause mortality (Whelton et al, 2018). Modifiable risk factors in patients 
with hypertension include cigarette smoking or secondhand smoking, diabetes 
mellitus, dyslipidemia, alcohol consumption, being overweight or obese, physical 
inactivity, excess stress, and poor diet choices, particularly ones high in sodium 
(AHA, 2017; Whelton et al, 2018). Common hereditary and physical risk factors 
include the presence of chronic kidney disease, diabetes, family history of 
hypertension, increased age, low socioeconomic status, male sex, obstructive sleep 
apnea, and psychosocial stress (AHA, 2017; Whelton et al, 2018).  
High blood pressure is associated with a heavy economic burden. The cost 
of health care services, medications for treatment, and missed days of work related 
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to hypertension costs the United States 48.6 billion dollars each year (CDC, 2016). 
The AHA projected that the cost of care for hypertension will increase to a total 
projected annual cost of 200.3 billion dollars in 2030, which is a 286% increase 
from 2010 (Heidenreich et al, 2011).  
With the added responsibility of national quality health initiatives pushing 
for better blood pressure control, it is crucial that patients who have hypertension 
or who are at risk for developing hypertension learn to monitor their blood 
pressure at home. Healthy People is a well-known national initiative managed by 
the Office of Disease Prevention and Health Promotion. Every ten years, Healthy 
People sets measurable objectives and goals driven by best available knowledge 
and literature to improve practice and the health of the nation (ODPHP, 2019). 
There are six objectives in Healthy People 2020 related to high blood pressure, 
one of which is considered a Leading Health Indicator. This priority issue is to 
achieve 61.2% blood pressure control amongst United States adults diagnosed 
with hypertension. In 2008, only 43.7% of United States adults with hypertension 
had their blood pressure under control. The 2013-2016 NHANES data showed 
control to only be at 47.8%, far below the target of 61.2% (ODPHP, 2019).  
National Guidelines 
Over the last twenty years, there have been three guidelines published in 
the United States for hypertension prevention and management. The Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) was published in 2003 (see Table 1). A 
coalition of 39 professional organizations and 7 federal agencies convened to 
review observational studies and clinical trials to create a guideline for clinicians 
to classify and treat hypertension (Chobanian et al., 2003). Methodology was 
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through nonsystematic literature review and recommendations were based on 
expert committee consensus (James et al., 2014). Pharmacologic treatment of 
hypertension, according to JNC 7, was initiated at Hypertension Stage 1, when the 
patient had a SBP of 140 mmHg or a DBP of 90 mmHg, unless they had diabetes 
or chronic kidney disease. Patients with diabetes or chronic kidney disease had 
more aggressive treatment guidelines in which their goal SBP was less than 130 
mmHg and their goal DBP was less than 80 mmHg (Chobanian et al., 2003). The 
guideline includes a brief discussion regarding the use of ambulatory or home 
blood pressure monitoring to evaluate for white coat hypertension, as well as a 
short excerpt on lifestyle modifications (Chobanian et al., 2003). In regard to 
pharmacologic treatment, JNC 7 recommended thiazide diuretics as the first-line 
treatment for hypertension (Chobanian et al., 2003).  
Table 1  
 
2003 JNC 7 Hypertension Guidelines: Blood Pressure Categories 
Blood Pressure Category Systolic (mmHg)  Diastolic 
(mmHg) 
Normal Less than 120 AND Less than 80 
Prehypertension 120 – 139 OR 80 - 89 
Hypertension Stage 1 140 - 159 OR 90 - 99 
Hypertension Stage 2 160 or higher OR 100 or higher 
Hypertensive Crisis 180 or higher OR 120 or higher 
In 2014, the Eighth Joint National Committee (JNC 8) reviewed and 
synthesized scientific evidence from randomized controlled trials to revise JNC 7 
(James et al., 2014). The definition for hypertension remained the same at a SBP 
of 140 mmHg and a DBP of 90 mmHg. The JNC 8 guideline increased the 
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threshold goal for patients with diabetes and chronic kidney disease to the same as 
the general population, at a SBP of 140 mmHg and a DBP of 90 mmHG (James et 
al., 2014). The only group whose goal was different than the general population 
were adults 60 years of age or older, in which their goal was specified at a SBP 
less than 150 mmHg and a DBP less than 90 mmHg (James et al., 2014). In 
addition to thiazide diuretics, angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, and calcium channel blockers were added for use as 
first-line treatment for hypertension (James et al., 2014).  
A systematic review by the AHA, ACC, and the National Heart, Lung, and 
Blood Institute (NHLBI) lead to the publication of the 2017 Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in 
Adults (Whelton et al, 2018). It was intended as an update to the 2003 JNC 7 
guideline. The guideline aggressively lowers the threshold for the diagnosis of 
hypertension to a SBP of 130 mmHg and a DBP of 80 mmHg in the general 
population, despite medical history, age, or comorbidities (see Table 2) (Whelton 
et al., 2018). The terminology ‘elevated blood pressure’ replaced 
‘prehypertension,’ also with a lower threshold in definition (see Table 2). 
Treatment parameters varied, with a large emphasis on lifestyle modifications 
through diet, exercise, alcohol restriction, and smoking cessation in all patients 
regardless of their blood pressure category (Whelton et al., 2018). This was the 
first guideline that recommended calculating the ten-year cardiovascular risk score 
when considering pharmacologic treatment for patients with Hypertension Stage 1 
(Whelton et al., 2018). This was also the first guideline whose blood pressure 
screening workflow included the use of home or ambulatory blood pressure 
monitoring to consider the diagnoses of white coat hypertension and masked 
hypertension (Whelton et al., 2018). 
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Table 2 
 
2017 AHA / ACC Hypertension Guidelines: Blood Pressure Categories 
Blood Pressure Category Systolic 
(mmHg) 
 Diastolic 
(mmHg) 
Normal Less than 120 AND Less than 80 
Elevated Blood Pressure 120 – 129 AND Less than 80 
High Blood Pressure (Hypertension) 
Stage 1 
130 – 139 OR 80 – 89 
High Blood Pressure (Hypertension) 
Stage 2 
140 or higher OR 90 or higher 
Hypertensive Crisis 180 or higher OR 120 or higher 
Theoretical Framework: The Health Belief Model 
The health belief model was developed by social psychologists Hochbaum, 
Kegels, and Rosenstock in the 1950s (Hochbaum et al, 1952). This was a time 
when public health programs were being implemented but underutilized. Despite 
the availability of low or no cost health programs, the population was not 
participating in preventive initiatives, including influenza and polio vaccinations, 
cervical cancer screening, and tuberculosis screening (Rosenstock, 1974). The 
health belief model aimed to explain why patients chose to participate in or 
withdraw from services by exploring the beliefs and attitudes that influenced 
decision making (Hochbaum et al., 1952). Since the 1950s, the health belief model 
has evolved beyond utilization in preventive health and has been used to explain 
and predict behavior directed toward compliance in treatment of chronic illness. 
The health belief model is composed of six main concepts, all of which influence a 
person’s readiness to act or change their behavior. These concepts are perceived 
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susceptibility, perceived severity, perceived benefits, perceived barriers, cue to 
action, and self-efficacy (Glanz et al., 2018). 
Specific to hypertension, the health belief model has been used in literature 
to study medication adherence, health promotion, and to help inform educational 
programs for hypertension. A cross-sectional study in a rural city in Iran found 
that only 24% of a sample of 671 participants with hypertension adhered to their 
medication regimen (Kamran et al., 2014). The patients more likely to adhere to 
their treatment plan were patients who perceived that they were susceptible to 
having hypertension, and that the benefit of treatment outweighed their perceived 
severity of having hypertension. Results showed the value and importance of 
patient perceptions on hypertension and medication. Education should be 
individualized and tailored according to patient perceptions in order to improve 
medication adherence. Thalacker (2011) used the health belief model as a tool to 
understand Hmong culture and what influenced their behaviors related to 
hypertension treatment. Through the health belief model, she was able to suggest 
an educational program facilitated by health care providers geared to empower the 
Hmong people to choose health-promoting behaviors related to hypertension 
(Thalacker, 2011).  
For this quality improvement project, the health belief model was used as a 
theoretical framework to help guide Stanford Health Care’s blood pressure 
screening workflow. The health care team evaluated each of the concepts within 
the health belief model to inform the design of the blood pressure screening 
workflow. In doing so, the workflow was designed to inspire participation in the 
quality improvement project, as well as empower patients to actively engaged in 
their health by learning how to monitor and understand their blood pressure 
readings in hopes to trigger healthy lifestyle choices.  
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Perceived Susceptibility and 
Perceived Severity 
Perceived susceptibility refers to a person’s belief in the likelihood of 
having a disease or condition (Glanz et al., 2018). Patients who have hypertension 
generally feel well without any noticeable symptoms. Because of this, there is 
little motivation for patients who have hypertension, or who are at risk for 
developing hypertension, to comply with pharmacologic treatment or lifestyle 
modification recommendations. In order for patients to act, they must accept that 
they may be susceptible to hypertension and its sequelae. The hypertension 
screening workflow takes this into account by educating every participant during 
their clinic visit on the meaning of hypertension and the consequences of target-
organ damage if left untreated.  
Perceived Benefits and Perceived 
Barriers 
Perceived benefits refer to the belief that taking action toward prevention or 
treatment of disease will reduce a person’s susceptibility or severity of the disease 
(Glanz et al., 2018). The treatment for hypertension includes lifestyle 
modifications and health promotion in every patient regardless of what stage 
hypertension they have. Pharmacologic intervention is recommended in patients 
with Hypertension Stage 2, or in patients with Hypertension Stage 1 with certain 
comorbidities or a high cardiovascular risk score (Whelton et al., 2018). Treatment 
adherence is dependent on the patient believing that the benefits of treatment 
outweigh the barriers and risks. The hypertension screening workflow eliminates 
three common barriers in home blood pressure monitoring: the out of pocket cost 
of a home blood pressure device, the concern of correct usage, and the concern of 
accurate calibration (Kronish et al., 2017; Tirabassi et al., 2013). The device is 
provided to the patient at no cost, the patient is taught how to utilize the home 
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blood pressure device, return demonstration of use in the clinic is encouraged, and 
the device calibration is validated against the clinic automated device in the clinic 
in front of the patient.  
Cue to Action 
Cue to action refers to internal or external factors that influence one to take 
action (Glanz et al., 2018). The cue to action for this quality improvement project 
is the clinic intervention of providing patients with home blood pressure monitors. 
As the patient monitors their blood pressure at home, they witness first-hand the 
variations in their blood pressure readings, whether they are normal or high. This 
awareness cues them to take their blood pressures seriously, prompting them to 
make the changes needed to prevent or treat their high blood pressure.  
Self-Efficacy 
Self-efficacy refers to the confidence in an individual to successfully 
perform an action or behavior change (Glanz et al., 2018). Self-efficacy is an 
important concept in hypertension management. In giving a patient a home blood 
pressure monitor, the clinic promotes self-efficacy by actively engaging the patient 
in their health. In promoting self-efficacy, the patient becomes confident in self-
care, has an understanding of their home blood pressure readings and implications 
of untreated high blood pressure, and is empowered to execute lasting lifestyle 
changes to reduce their cardiovascular risk. 
 CHAPTER 2: LITERATURE REVIEW 
Literature was sought to investigate patient and provider barriers to home 
blood pressure monitoring, prevalence and risk factors associated with masked and 
white coat hypertension, and the clinical significance for diagnosing masked and 
white coat hypertension.  
Home and Ambulatory Blood Pressure Devices 
There are two approved devices to measure blood pressure readings outside 
of the clinic setting: ambulatory blood pressure monitoring (ABPM) and home 
blood pressure monitoring (HBPM) (Shimbo et al., 2015). ABPM measures blood 
pressure every fifteen to thirty minutes over a 24-hour period during daily routine 
activities, whereas, HBPM assesses blood pressure at specific times while the 
person is seated and resting. ABPM and HBPM provide data used to calculate 
mean out-of-clinic blood pressure in order to identify a person’s hypertensive 
phenotype. There are four primary hypertensive phenotypes: normotension, 
sustained hypertension, white coat hypertension and masked hypertension 
(Shimbo et al., 2015).  
The final recommendation statement for high blood pressure screening in 
adults from the USPSTF confirms that there is more evidence that supports ABPM 
as superior to HBPM; however, if ABPM is unavailable HBPM is an acceptable 
alternative (Siu, 2015). Since this statement released in 2015, hypertension 
guidelines have increasingly supported the use of HBPM in the management of 
hypertension, including the European Society of Hypertension 2018 guideline, the 
United States AHA and ACC 2017 guideline, and the United Kingdom National 
Institute for Health and Care Excellence guideline (NICE) (Williams et. Al, 2018; 
Whelton et al., 2018; NICE, 2019).  
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Challenges of Ambulatory Blood 
Pressure Monitoring 
There are barriers to consider when utilizing ABPM for both the primary 
care provider and the patient. Primary care providers voiced concerns regarding 
the cost of ABPM, willingness or ability of the patient to successfully complete 
testing, and concerns about the accuracy and benefits of testing (Kronish et al., 
2017). ABPM is not widely available in primary care settings, often requiring a 
referral to a hypertension center or office that has the capacity to perform the test 
(White & Gulati, 2015). Insurance companies do not always reimburse for ABPM 
and the reimbursement rate is low (Kent et al., 2014). The perception of primary 
care providers regarding the lack of patient willingness for testing is disputed in 
Carter et al.’s qualitative study. Patients voiced that having the option for ABPM 
or HBPM was an opportunity for them to engage in their care and because of this, 
they would agree to testing if recommended by the primary care provider (Carter 
et al., 2018). Patients want to actively participate in their health; however, this is 
difficult to do without time and resources provided by their primary care. Barriers 
described on the patient side included testing reliability and concerns regarding 
night-time blood pressure readings as being disruptive (Carter et al., 2018). 
Common reported disadvantages from participants who underwent ABPM 
included pain, skin irritation, bruising, and interference with sleep, so much so that 
some patients removed the device during the night (Viera et al., 2011).  
Challenges of Home Blood Pressure 
Monitoring 
Home blood pressure devices are more widely available than ABPM, as 
they can be purchased in retail stores and pharmacies. Like ABPM, there are 
barriers to consider in respect to the primary care provider and patient. Primary 
care providers voiced concerns regarding compliance with correct methodology 
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for blood pressure measurement, accuracy of test results, out of pocket costs for 
the devices, and the time needed to instruct patients on home blood pressure 
monitoring protocol (Bonafini and Fava, 2015; Kronish et al., 2017). Physicians 
also voiced concerns about the use of non-validated HBPM and the potential for 
patient preoccupation in blood pressure monitoring which may lead to anxiety 
(Cheng et al, 2003; Logan et al., 2008). HBPM allows for more data points over a 
longer period of time, which may be an advantage or disadvantage. ABPM only 
provides short-term blood pressure variability over 24-hours, which may not be an 
appropriate time frame for diagnosis of this chronic condition (Bonafini & Fava, 
2015; White & Gulati, 2015). Patients primary concern regarding HBPM was the 
out of pocket cost if the device was not covered by insurance (Carter et al., 2018; 
CDC, 2013). Because of this, many patients preferred to have ABPM over HBPM 
if it was covered by their insurance, to minimize out of pocket costs (Carter et al., 
2018; CDC, 2013).  
White Coat Hypertension 
Prevalence 
White-coat hypertension was first described in United States literature in 
1984 (Kleinert et al., 1984). Epidemiologic data through the USPSTF estimates 
that 15 to 30% of United States adults have white coat hypertension (Piper et al., 
2015). 
Risk Factors 
It is proposed that white coat hypertension is due to sympathetic nervous 
system activation during encounters with health care providers (Grassi et al., 
2013). Similarly, Bloomfield and Park attribute the white-coat effect to a neuro-
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endocrine reflex conditioned by anticipation of having one’s blood pressure taken 
and fear of what the measurement may indicate (2017). Another determinant of 
white coat hypertension is age, with patients over the age of 60 at higher risk of 
having white coat hypertension compared to younger participants (Tanner et al., 
2016). 
Screening 
Current USPSTF hypertension screening recommendations and the 2017 
AHA and ACC guideline recommends screening for white coat hypertension with 
ABPM or HBPM for any patient with elevated or high blood pressure readings in 
the clinic setting (Siu, 2015; Whelton et al., 2018).  
Masked Hypertension 
Prevalence 
Masked hypertension is a newly appreciated phenomenon, first mentioned 
in United States literature in 2002 (Pickering et al., 2002). Wang et al. pooled data 
from the Masked Hypertension study and the NHANES to understand the burden 
of masked hypertension on the United States (2017). Based on the data, they 
estimated that 12.3% of United States adults have masked hypertension (Wang et 
al., 2017). If this data is accurate, then about 1 in every 8 United States adult with 
normal or elevated blood pressure in the clinic actually has masked hypertension, 
resulting in millions of adults misclassified as not having hypertension. This is the 
only study that provides an estimate of masked hypertension prevalence in the 
United States. A systematic review of five population-based studies, four in 
Europe and one in Japan, found prevalence of masked hypertension in the general 
population to range anywhere between 14% to 30% (Peacock et al., 2014). 
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Risk Factors 
The risk factors for masked hypertension are consistent with the risk factors 
for sustained hypertension. The Jackson Heart Study evaluated masked 
hypertension in a community-based cohort of African Americans residing in 
Jackson, Mississippi (Bromfield et al., 2016). Life’s Simple 7 questionnaire was 
used to identify modifiable risk factors and included body mass index (BMI), 
physical activity, diet, cigarette smoking, clinic-measured blood pressure, total 
cholesterol, and a fasting glucose. Of the participants, 30.5% had masked 
hypertension. Masked hypertension was more likely to occur in patients who had 
worse overall cardiovascular health: poor physical activity, positive smoking 
status, prehypertenion, and poor diet (Bromfield et al., 2016). Similarly, in two 
separate studies, persons with a sedentary lifestyle, obesity, and low exercise 
tolerance were prone to having masked hypertension (Schultz et al., 2011; 
Sharman et al., 2011).  
Additionally, alcohol consumption, caffeine consumption, and cigarette 
smoking are risk factors for masked hypertension (Franklin et al., 2015). Stress or 
job strain also contributed to normal or elevated blood pressure readings in the 
clinic but high blood pressure readings outside of the clinic setting (Landsbergis et 
al., 2013). Conditions that have been linked to masked hypertension include 
metabolic syndrome, diabetes mellitus, chronic kidney disease, and obstructive 
sleep apnea (Franklin et al., 2015).  
There is conflicting data whether age is a predictor for masked 
hypertension. Data solely from the Masked Hypertension Study found that of the 
888 healthy, middle-aged, employed participants not on medication for 
hypertension, the prevalence of phenotypes was 79.8% with normotension, 14.9% 
for masked hypertension, 1.0% with white-coat hypertension, and 4.3% with 
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sustained hypertension (Schwartz et al., 2016). The majority of patients with 
masked hypertension were young adults (Schwartz et al, 2016). On the other hand, 
masked hypertension was found to be more prevalent among older adult males and 
in patients with prehypertension or diabetes from data pooled from both the 
Masked Hypertension Study and the NHANES (Wang et al., 2017).  
A common predictor for masked hypertension was the presence of elevated 
blood pressure, formerly known as prehypertension, in the clinic setting (Shimbo 
et al., 2012; Redmond et al., 2016). Of the patients diagnosed with masked 
hypertension in the Masked Hypertension Study, 35% had a borderline elevated 
blood pressure reading in the clinic setting and only 8.9% of the patients had 
normal clinic blood pressure measurements (Shimbo et al., 2012). Similarly, of the 
patients diagnosed with masked hypertension in the Improving the Detection of 
Hypertension Study, 35.3% had elevated blood pressure readings in the clinic 
setting compared to 6.8% with normal clinic blood pressure measurements 
(Redmond et al., 2016).  
Screening 
Literature does not offer clear criteria on whom to screen to detect masked 
hypertension. Data was pooled from the Masked Hypertension Study, the 
Improving the Detection of Hypertension Study, and the Jackson Heart Study to 
determine the practicality of what parameters to use to screen for masked 
hypertension (Booth et al., 2016). Screening all patients with normal clinic blood 
pressure readings would result in 118.6 million (~78%) United States adults to 
undergo ABPM. On the other hand, if elevated clinic blood pressure was used as 
the criterion to screen for masked hypertension, 59.3 million (~39%) United States 
adults wound undergo ABPM. If the upper range of prehypertension was used as 
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the criterion for masked hypertension screening, then 20.3 million (13%) United 
States adults would undergo ABPM. Alternatively, instead of using clinic blood 
readings as the sole criterion for masked hypertension screening, the practitioner 
can take a different approach by only screening patients who have more risk 
factors associated with masked hypertension (Booth et al., 2016). At this point, the 
ACC/AHA guideline recommends screening patients for masked hypertension 
using ABPM or HBPM if there is suspicion for masked hypertension and the 
patient has elevated blood pressure readings in the clinic (a SBP between 120 to 
129 mmHg and a DBP less than 80 mmHg) (Whelton et al., 2017).  
Clinical Significance of White Coat Hypertension 
and Masked Hypertension 
Masked hypertension is associated with increased adverse cardiovascular 
outcomes and target organ damage. Patients within the Jackson Heart Study who 
had masked hypertension compared to normotension had increased arterial, 
cardiac, and renal damage compared to patients with normotension as measured by 
carotid artery intimedia thickness, left ventricular mass index, and urinary albumin 
to creatinine excretion ratio, respectively (Diaz et al, 2014). Similarly, in a large, 
multiethnic, probability-based population cohort in the Dallas Heart Study, 
masked hypertension was associated with increased aortic stiffness, renal injury, 
and cardiovascular events as measured from aortic pulse wave velocity, cystatin C, 
and urinary albumin-to-creatinine ratio (Tientchu, 2015).  
There is conflicting evidence on whether or not white-coat hypertension is 
associated with higher cardiovascular risk. A study that investigated the 
cardiovascular outcomes in sustained hypertension, white coat hypertension, and 
normotension in the short and long term found increased cardiac and 
cerebrovascular risk in patients with sustained hypertension, but no significant 
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difference between this risk in patients with white coat hypertension versus 
normotension (Pierdomenico et al., 2008).  
More recent literature shows increasing evidence suggesting that white coat 
hypertension results in poor cardiovascular outcomes. Similar to masked 
hypertension, patients with white coat hypertension in the Dallas Heart Study were 
identified to have evidence of target organ damage with increased aortic stiffness, 
renal injury, and cardiovascular events (Tientchu, 2015). A comprehensive meta-
analysis examining target organ damage and its association with white coat 
hypertension found higher risk of cardiovascular disease and total mortality in 
patients with untreated white coat hypertension (Huang et al., 2017). A recent 
systematic review and meta-analysis published in the Annals of Internal Medicine 
found that untreated white coat hypertension is associated with a near double risk 
of cardiovascular events and all-cause mortality (Cohen et al., 2019).  
Summary 
The literature suggests that blood pressure screening strategies that rely 
solely on clinic blood pressure readings will misdiagnose patients with or without 
hypertension in regard to white coat and masked hypertension. Incorporating 
ABPM or HBPM in hypertension screening is necessary to correctly diagnose 
hypertensive phenotype. Almost all of the studies described in the literature review 
were performed prior to the publication of the 2017 AHA and ACC guideline on 
blood pressure management, therefore, data may actually underestimate the 
prevalence of hypertension in the general population. The literature published after 
the 2017 AHA and ACC guideline showed increasing evidence of poor 
cardiovascular outcomes associated with white coat hypertension. The 2017 
guideline lacks recommendations for treatment of white coat hypertension. 
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The studies on provider and patient attitudes regarding ABPM and HBPM 
are outdated, and no studies have been performed to address these barriers. Further 
studies are needed to identify better screening parameters for masked 
hypertension. There are no studies that evaluate the role of ABPM or HBPM in 
guiding anti-hypertensive treatment. Studies are needed to examine treatment 
options and outcomes specific to patients with masked hypertension and white 
coat hypertension.  
 
 CHAPTER 3: METHODOLOGY 
To address the problem of misdiagnosis of hypertension due to lack of 
home blood pressure monitoring, Stanford Health Care implemented a quality 
improvement project that provided patients with a home blood pressure device to 
monitor out of clinic blood pressure readings. The purpose of the project was to 
improve clinical care at Stanford Health Care by using home blood pressure 
monitoring as a way to assess for treatment control in patients already diagnosed 
with hypertension, or to verify the diagnosis of hypertension in patients not 
previously diagnosed.  
Stanford Health Care staff created a patient-centered, blood pressure 
screening workflow mirroring the 2017 AHA and ACC Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in 
Adults. The Stanford School of Medicine sponsored 30 brachial Omron 10 series 
blood pressure devices (Model: BP7450) to use for the quality improvement 
project. This model had been inspected and cleared by the United States Food and 
Drug Administration (FDA) and clinically validated according to protocols from 
the European Society of Hypertension – International Protocol and the Association 
for the Advancement of Medical Instrumentation (Omron, 2020).  
The workflow was implemented on January 2, 2019. Data was collected 
from the start of workflow implementation through August 31, 2019. Before 
collecting data, clinical site permission and institutional review board approval 
was obtained from both California State University (CSU) Fresno and Stanford 
School of Medicine. The quality improvement project was exempt from full 
review by the Committee for the Protection of Human Subjects from both CSU 
Fresno and Stanford School of Medicine because the project involved the study of 
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existing data, documents, and records routinely available to the investigator. Only 
the minimum data necessary for project evaluation was collected. Data was de-
identified and obtained from the patient electronic charts on-site on an encrypted 
computer, only accessible to the investigator. After data analysis completed, the 
collection log was permanently deleted. The data elements that were collected 
were clinic blood pressure, clinic phenotype, mean home blood pressure, home 
phenotype, age, sex, smoking status, BMI, alcohol status, whether the patient was 
on treatment for hypertension or not, and the time (days) from clinic visit to 
diagnosis and treatment plan.  
Subjects 
The subjects were full time employees of a large tech company. They all 
had health insurance and received care at their employer-based health clinic 
managed by Stanford Health Care. The professional spectrum included engineers, 
scientists, lawyers, and business strategists, ages 23 to 66.  
Inclusion Criteria 
Because of the limited amount of home blood pressure monitors that were 
available, the quality improvement project was limited to patients who presented 
to the clinic for their routine preventative physical or for a blood pressure specific 
complaint. Patients with a clinic blood pressure reading that was considered 
elevated (SBP greater than 120 mmHg and a DBP greater than 75 mmHg) or high 
(SBP greater than 130 mmHg or DBP greater than 80 mmHg) were considered for 
inclusion (see Appendix A for workflow diagram). Patients excluded from 
borrowing a blood pressure device from the clinic were patients with normal blood 
pressures (SBP less than120 mmHg and DBP less than 80) and patients who 
presented to the clinic for a problem-focused visit that was not blood pressure 
 22 
specific. Patients were given the option whether or not they wanted to utilize a 
clinic provided home blood pressure monitor or purchase their own blood pressure 
device for monitoring. Data was only collected from the patients who chose to 
borrow the clinic blood pressure device.  
Workflow 
For patients who presented to the clinic with a blood pressure specific 
complaint or for their routine preventative health physical, the patient was brought 
into the clinic room and asked to sit quietly for five minutes. The medical assistant 
took the patient’s blood pressure with Stanford Health Care electronic equipment. 
If the clinic reading met the criteria for inclusion, the medical assistant 
automatically re-checked the blood pressure with an Omron home blood pressure 
monitoring device. Quality was accurate if the diastolic blood pressure was +/- 3 
mmHg according to manufacturer standards. If the calibration was not according 
to manufacturer standards, quality was checked on a different Omron device. After 
verification that the Omron blood pressure device was correctly calibrated with the 
electronic equipment, the medical assistant notified the provider that the patient 
was ready for examination and eligible for HBPM based on clinic blood pressure 
measurement.  
During the office visit, the provider discussed the findings and implications 
of elevated or high blood pressure with the patient, and the need for confirmation 
of diagnosis through HBPM. Additionally, the patient was given instruction on 
lifestyle changes to improve blood pressure measurements. The patient was given 
the option to either purchase a blood pressure device or borrow the clinic Omron 
cuff to obtain out of clinic blood pressure measurements in order to confirm 
diagnosis of hypertension. The patient was then instructed on the proper way to 
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take their blood pressure at home using the Omron blood pressure device. It was 
recommended that the patient take three consecutive blood pressure readings. The 
first reading was to be discarded, and the average of the second and third reading 
was to be recorded into a blood pressure log. They were asked to do this twice 
daily, preferably before breakfast and before dinner, for at least three consecutive 
days after resting for five minutes. 
For follow up, the patient had the option to schedule an in-office 
appointment to review data and discuss results or send the data to the provider 
through the EPIC MyHealth Tracker system. The MyHealth Tracker system 
allowed the patient to input blood pressure data into their medical record, which 
automatically sends to the primary care provider. Upon receipt of the data, the 
primary care provider is able to calculate the mean home blood pressure. For 
patients already on anti-hypertensive medication, a normal or elevated blood 
pressure reading was considered controlled hypertension; a blood pressure in any 
hypertensive category was considered uncontrolled hypertension. For patients who 
had never been diagnosed with high blood pressure, the mean home blood 
pressure measurement allowed the primary care provider to diagnose hypertensive 
phenotype: normotension or elevated blood pressure, sustained hypertension, 
white coat hypertension, or masked hypertension. All patients who participated in 
the quality improvement project were given recommendations on lifestyle 
changes. Pharmacologic intervention was recommended according to the AHA 
and ACC 2017 guideline if indicated. The device was then returned to the clinic 
by the patient. Any saved data was cleared from the device. The machine, cuff, 
and tubing were wiped down with Sani-wipes, per policy. 
. 
 CHAPTER 4: RESULTS 
There were 114 patients who met the inclusion criteria for home blood 
pressure monitoring between January 2, 2019 and August 31, 2019. Of these 
patients, 16 were excluded from data analysis because they were still under 
possession of the clinic cuffs upon data collection.  
Sample Demographics 
Data was obtained from 98 patients who participated in the quality 
improvement project. The age range was between 23 and 66 years of age, with a 
mean age of 44 (SD = 9.29). There were 10 female and 88 male participants. Of 
the sample, there were 7 patients who were current cigarette smokers, 14 former 
smokers, and 77 non-smokers. The BMI ranged from 16.54 to 42.69, with a mean 
of 27.76 (SD = 4.77). Alcohol intake varied (see Figure 1). 
 
Figure 1. Number of patients categorized by their reported average weekly alcohol 
consumption in standard drinks per week.  
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Of the 98 participants, 30% (n=29) already had the diagnosis of hypertension and 
were on blood pressure medication while 70% (n=69) had never been diagnosed 
with hypertension (see Figure 2).  
 
Figure 2. Number of patients previously diagnosed with hypertension versus 
number of patients with elevated blood pressure readings without the diagnosis of 
hypertension. 
Data Analysis 
Patients who already the diagnosis of hypertension and were on anti-
hypertensive medications were given home blood pressure monitors to assess for 
treatment control. Patients who had never been diagnosed with hypertension were 
given home blood pressure cuffs to confirm hypertensive phenotype. Therefore, 
data analyses between these two groups were performed separately. 
Patients Already Diagnosed with 
Hypertension 
Home blood pressure monitoring was implemented in 29 patients already 
diagnosed with hypertension to assess for treatment control. After home blood 
pressure monitoring, 31% (n=9) had controlled hypertension and 69% (n=20) had 
uncontrolled hypertension (see Figure 3). The patients with controlled 
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hypertension were advised to continue their current medication regimen and 
lifestyle modifications were reinforced. All 20 patients who had uncontrolled 
hypertension agreed to a medication dose change. 
 
Figure 3. Of the patients already diagnosed with hypertension, the number of 
patients with controlled hypertension versus uncontrolled hypertension after 
completion of home blood pressure monitoring.  
The number of days was documented from the patient’s clinic visit to when 
a diagnosis and treatment plan was made. There was a clear outlier of 140 days for 
unknown reason. Removing this outlier, the time (days) to treatment intervention 
ranged from 3 to 35 day, with a mean (days) of 12.7 (SD = 8.27). The median was 
11 days from clinic visit to diagnosis and treatment plan.  
Patients Without the Diagnosis of 
Hypertension 
Home blood pressure monitoring was implemented in 69 patients who had 
never been diagnosed with hypertension. After home blood pressure monitoring, 
65% (n=45) had sustained hypertension, 20% (n=14) had white coat hypertension, 
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and 12% (n=8) had elevated blood pressure or prehypertension (see Figure 4). No 
patients had masked hypertension. Two patients were classified to have 
normotension because they had elevated blood pressure readings at their clinic 
visit with a normal mean home blood pressure reading.  
 
Figure 4. Patients without the diagnosis of hypertension categorized by 
hypertensive phenotype after the home blood pressure monitoring intervention.  
There were 45 patients that were newly diagnosed with hypertension after 
home blood pressure monitoring was completed. Of these patients, 67% (n=30) 
had Hypertension Stage 1 and 33% (n=15) had Hypertension Stage 2. Of the 
patients diagnosed with Hypertension Stage 1, 9 patients agreed to implement 
medication therapy in addition to lifestyle modifications, and 21 patients opted to 
work on lifestyle modifications with agreement to re-evaluate the treatment plan in 
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3 to 6 months (see Figure 5). The time (days) from clinic visit to treatment 
intervention ranged from 6 to 70 days, with a mean (days) of 16.8 (SD = 13.41), 
and a median of 14 days. In the patients diagnosed with Hypertension Stage 2, 12 
patients agreed to implement medication therapy in addition to lifestyle 
modifications, and 3 patients opted to work on lifestyle modifications with 
agreement to re-evaluate the treatment plan in 3 months. The time (days) from 
clinic visit to treatment intervention ranged from 4 to 34 days, with a mean (days) 
of 11.73 (SD = 8.67), and a median of 7 days (see Figure 5). 
 
Figure 5. Number of patients newly diagnosed with hypertension according to 
stage, and the treatment plan implemented after home blood pressure monitoring 
was performed.  
 
 CHAPTER 5: DISCUSSION AND CONCLUSION 
Discussion 
Implementation of home blood pressure monitoring increased awareness of 
the importance of hypertension and allowed for education of risk reduction 
strategies in all 116 patients who met the inclusion criteria for the quality 
improvement project. All patients who participated took away an understanding of 
what their blood pressure readings meant and how to make healthy lifestyle 
choices to reduce their cardiovascular risk.  
Home blood pressure monitoring was used to assess for treatment control in 
patients already diagnosed with hypertension. All of the patients on anti-
hypertensive medications diagnosed with uncontrolled hypertension agreed to a 
medication dose change. This suggests that home blood pressure monitoring was 
not only effective in assessing for treatment control, but it helped allow the patient 
to recognize the need for treatment adjustment to improve control.  
Home blood pressure monitoring was also used to evaluate hypertensive 
phenotype in patients undiagnosed with hypertension. Home blood pressure was 
very useful in verifying the hypertensive phenotype in patients with sustained 
hypertension and white coat hypertension. Of the 69 patients undiagnosed with 
hypertension, over half of them (65%, n=45) were confirmed to have sustained 
hypertension. The percentage of patients diagnosed with white coat hypertension 
(20%) was consistent with the epidemiologic data estimate of 15% to 30% of the 
United States population having white coat hypertension. Furthermore, of the 45 
patients newly diagnosed with hypertension, home blood pressure monitoring 
prompted 46% (n=21) to initiate medication therapy. This suggests that home 
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blood pressure monitoring may have had a positive role in patient recognition and 
acceptance of diagnosis.  
The most profound impact of providing patients with home blood pressure 
monitors was the turnaround time from clinic visit to diagnosis and treatment plan. 
Anecdotally, in the investigator’s practice, it could take months to years to confirm 
whether or not a patient had sustained hypertension versus white coat hypertension 
prior to implementation of this quality improvement project. By providing a 
patient with a clinic loaned blood pressure device, a diagnosis and treatment plan 
was made, on average, within two weeks.  
Limitations 
This was a quality improvement project; therefore, the author is unable to 
statistically quantify the significance of findings. It was made very clear to CSU 
Fresno and Stanford School of Medicine that the undertaking was a quality 
improvement project with the purpose of implementing a data-guided intervention 
to bring immediate improvements in health delivery as opposed to research 
designed to contribute to generalizable knowledge. Because this was not a 
research study, the investigator is unable to correlate any associations between 
hypertension and alcohol consumption, BMI, or cigarette smoking.  
Of the 114 patients who participated in the project, 16 of them were 
excluded because they still possessed the clinic cuffs at the start of data collection. 
Unfortunately, due to limited overhead, it was very difficult to track and request 
the return of these cuffs. Project data did not include the patients who chose to use 
their own home blood pressure devices. Lastly, Stanford School of Medicine 
sponsored 30 Omron blood pressure devices to implement the quality 
improvement project; therefore, for clinics interested in replicating the project, 
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there may be a cost barrier to obtain a supply of blood pressure devices for their 
clinic.  
Future Recommendations 
The ability to monitor blood pressure readings outside of the clinic 
environment is continuously developing. With the push toward home blood 
pressure or ambulatory blood pressure monitoring, the diagnosis of hypertension 
depends on blood pressure variation throughout the day. In addition to ambulatory 
and home blood pressure monitoring, there are devices available that have the 
capacity to automatically transmit blood pressure reading directly into the patient’s 
medical record. There are newer devices yet to be FDA approved where the 
patient wears a patch on their chest that can monitor their blood pressure, heart 
rhythm, and their blood oxygen saturation 
This quality improvement project alone has great potential for expansion. 
The positive results have already prompted interest for sponsorship of more blood 
pressure devices. Future analyses can focus on provider and patient attitudes 
regarding home blood pressure monitoring. Investigation of home blood pressure 
monitoring in guiding anti-hypertensive treatment is also promising. The United 
States healthcare system is complex and rapidly evolving as more and more clinics 
are increasing services through telemedicine. Several patients in this project chose 
to report their home blood pressure readings to the provider through the MyHealth 
tracker; it is possible to create a fully-telehealth workflow for blood pressure 
management.  
Conclusion 
Management of hypertension is a public health challenge. Without home 
blood pressure monitoring, it is impossible to correctly diagnose and treat 
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hypertension, which is essential for hypertension management. Providing patients 
with a home blood pressure monitor is a simple and effective way to assess for 
treatment control in patients already diagnosed with hypertension and to validate 
hypertensive phenotype in patients undiagnosed with hypertension, particularly 
with white coat hypertension and sustained hypertension. Furthermore, it allows 
the patients to become active participants in their health and increases awareness 
of the silent killer known as hypertension. Providing home blood pressure 
monitors as a screening tool for hypertension has the potential to reduce morbidity 
and mortality, reduce economic burden, and contribute to national quality 
initiatives that contribute to the overall health of the nation.  
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